Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q1 FY23 results · Apr–Jun 2022
Lincoln Pharmaceuticals reported revenue from operations of ₹123.47 crore and net profit of ₹15.01 crore for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 123.47 | — | — | 102.59 | +20.4% |
| Other income | 6.49 | — | — | 1.89 | +243.5% |
| Total income | 129.97 | — | — | 104.48 | +24.4% |
| Profit before tax | 20.93 | — | — | 16.77 | +24.8% |
| Net profit for the period | 15.01 | — | — | 11.02 | +36.2% |
| EPS, basic (₹) | 7.49 | — | — | 5.50 | +36.2% |
| Net margin (%) | 12.2 | — | 10.7 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 123.47 | 119.74 | +3.1% | 102.54 | +20.4% |
| Other income | 6.49 | 2.32 | +179.8% | 1.89 | +243.5% |
| Total income | 129.97 | 122.06 | +6.5% | 104.43 | +24.4% |
| Profit before tax | 20.93 | 24.49 | −14.6% | 16.76 | +24.8% |
| Net profit for the period | 15.01 | 17.38 | −13.6% | 11.02 | +36.2% |
| EPS, basic (₹) | 7.49 | 8.69 | −13.8% | 5.50 | +36.2% |
| Net margin (%) | 12.2 | 14.5 | 10.8 |
Consolidated
- Filed with BSE
- 23 Aug 2022, 17:49 IST
- Board meeting
- 09 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 Aug 2022, 17:49 IST
- Board meeting
- 09 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE